source
- Novartis and Ionis's pelacarsen fails to cut heart events despite lowering Lp(a) levelsNovartis and Ionis reported that pelacarsen, an RNA therapy aimed at lowering lipoprotein(a), did not reduce major cardiovascular events in a Phase 3 trial of over 8,000 patients. The study compare…
- Fi recalls dog supplements over possible Salmonella contaminationFi, a New York-based company, announced a recall of its dog supplement products due to potential Salmonella contamination linked to an ingredient supplied to its manufacturer. The manufacturer has…